Meents, J.E., et al. (2019) The Role of NaV1.7 in Human Nociceptors: Insights from Human Induced Pluripotent Stem Cell-Derived Sensory Neurons of Erythromelalgia Patients. Pain, 160, 1327-1341.
https://doi.org/10.1097/j.pain.0000000000001511

has been cited by the following article:

• TITLE: “Atropisomeric” Drugs: Basic Concept and Example of Application to Drug Development

  AUTHORS: Robert B. Raffa, Joseph V. Pergolizzi Jr., Robert Taylor Jr.

  KEYWORDS: Atropisomer, Chirality, Pharmacotherapy, Drug Development, NaV1.7 Inhibitor

  JOURNAL NAME: Pharmacology & Pharmacy, Vol.11 No.1, January 7, 2020

  ABSTRACT: Many therapeutic drugs are racemates; i.e. they are chiral molecules consisting of “left”- and “right-handed” enantiomers (stereoisomers that are mirror images of each other, and are non-superimposable). In some cases, both enantiomers of the drug contribute to some extent (or equally) to the therapeutic effect; in other cases they contribute not at all. The same is true for the adverse effects of racemate drugs: the adverse effects of a racemate drug can be greater-than, less-than, or equal to one or the other enantiomer. An unusual situation arises when a drug consists of “atropisomers”, stereoisomers arising because of hindered rotation about a single chemical bond. We summarize the concept of atropisomerism, and give examples.